Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the 40th Annual J.P. Morgan Healthcare Conference on Jan. 10, 2022, at 11:15 a.m. Eastern Time. CEO Kevin Gorman will lead the presentation. Investors can watch the live presentation via the company’s website, with a replay available about one hour post-event, archived for one month. Neurocrine focuses on developing treatments for neurological, endocrine, and psychiatric disorders, with an FDA-approved portfolio addressing conditions like tardive dyskinesia and Parkinson's disease.

SAN DIEGO, Jan. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual 40^th Annual J.P. Morgan Healthcare Conference at 11:15 a.m. Eastern Time on Monday Jan. 10, 2022. Kevin Gorman, Chief Executive Officer, will present at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301452912.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences present at the J.P. Morgan Healthcare Conference?

Neurocrine Biosciences will present on January 10, 2022, at 11:15 a.m. Eastern Time.

Who will represent Neurocrine Biosciences at the conference?

CEO Kevin Gorman will represent Neurocrine Biosciences at the conference.

How can I access the Neurocrine Biosciences conference presentation?

The presentation can be accessed live on Neurocrine's website under the Investors section.

Will there be a replay of Neurocrine Biosciences' presentation?

Yes, a replay will be available approximately one hour after the presentation and archived for about one month.

What is Neurocrine Biosciences' focus area?

Neurocrine Biosciences focuses on developing treatments for neurological, endocrine, and psychiatric disorders.